By Fineline Cube 
GRIT Biotechnology and Sino-US biotech company Drug Farm jointly announced a deep agreement to collaborate on the development and commercialization of an AI‑native platform, the companies said. The two companies will co‑create a world‑leading AI‑native biotech R&D platform named KunEvo.
Deal Overview
| Item | Detail |
|---|---|
| Parties | GRIT Biotechnology × Drug Farm (Sino‑US biotech) |
| Deal Type | Deep collaboration agreement on development and commercialization of an AI‑native platform |
| Platform Name | KunEvo |
| Positioning | World‑leading AI‑native biotech R&D platform |
| Announcement Date | 24 Jul 2026 |
Platform Scope – KunEvo
KunEvo is designed to accelerate the industrial application of underlying AI for Science technologies across three frontier areas:
| Focus Area | Objective |
|---|---|
| First‑in‑Class Novel Target Discovery | Identify and validate novel drug targets via AI‑driven discovery |
| Tumor Cell Therapies | Accelerate development of cell‑based cancer therapies |
| Neoantigen Cancer Vaccines | Enable AI‑powered design of personalized neoantigen vaccines |
Core Innovation – Bridging Dry Lab and Wet Lab
By bridging the gap between dry‑lab computation and wet‑lab experimentation, the partners aim to propel drug R&D from traditional monthly iteration cycles into a new era of real‑time, second‑by‑second iterations.
| Traditional R&D | KunEvo Target Paradigm |
|---|---|
| Monthly iteration cycles | Real‑time, second‑by‑second iterations |
| Disconnected computation and experimentation | Integrated dry‑lab / wet‑lab closed loop |
| Sequential discovery workflows | Parallel AI‑driven discovery and validation |
Strategic Rationale & Market Impact
- AI‑Native Positioning: Unlike bolt‑on AI tools applied to conventional pipelines, KunEvo is built as an AI‑native platform from the ground up — positioning it to redefine R&D workflow architecture rather than merely accelerate existing processes.
- Iteration Speed as Competitive Moat: The ambition to move drug R&D from monthly to second‑by‑second iteration cycles represents a step‑change in discovery velocity, with the potential to materially compress time‑to‑candidate across modalities.
- Frontier Modality Coverage: Spanning first‑in‑class target discovery, tumor cell therapies, and neoantigen cancer vaccines, the platform targets three of the most scientifically demanding and commercially attractive areas in oncology.
- Industrial Application Focus: The explicit emphasis on industrial application of AI for Science technologies signals a pragmatic orientation toward deployable, commercializable R&D infrastructure — not just research capability.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the KunEvo platform’s development, performance, and commercialization potential. Actual results may differ due to risks including technology development outcomes, validation timelines, and competitive dynamics.-Fineline Info & Tech